drugset / Trial / NCT03794492
Impact of Lymphocyte Anti-metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome
NaSingle-groupOpen-labelTreatment
Summary
Efficacy and Safety of My-Rept® (Mycophenolate Mofetil 500mg/Tab. or 250mg/Cap.) in Combination with Tacrolimus, Methylprednisolone, Simulect in Kidney Transplant Patients
Timeline
- Start
- 2018-03-31
- Primary completion
- 2022-07-22
- Completion
- 2023-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycophenolate Mofetil | Small molecule | 1 g | Oral |
| Background | Basiliximab | Monoclonal antibody | 20 mg | — |
| Background | Methylprednisolone | Other / unclassified | 500 mg | — |
| Background | Prednisolone | Other / unclassified | 5 mg | — |
| Background | Tacrolimus | Small molecule | — | Oral |
Indications
No indication recorded.